Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Myriad Genetics , Inc. (NASDAQ:MYGN) stock has reached a 52-week low, touching down at $7.28, as the company faces a challenging period marked by a significant downturn in its market valuation to $673 million. According to InvestingPro analysis, the stock’s RSI indicates oversold territory, while management has been actively buying back shares. Over the past year, Myriad Genetics has seen its stock price plummet, with a stark 1-year change showing a decrease of -60.76%. This considerable drop reflects investor concerns, though analyst targets suggest potential upside, ranging from $9 to $29 per share. The 52-week low serves as a critical indicator of the stock’s performance, setting a new benchmark for its trading range over the past year and underscoring the urgency for strategic initiatives to bolster investor confidence and company growth. Despite current challenges, InvestingPro analysis indicates the company is undervalued, with analysts forecasting a return to profitability this year. Discover 10+ additional exclusive insights and detailed analysis in the Pro Research Report, available with an InvestingPro subscription.
In other recent news, Myriad Genetics has been in the spotlight due to several developments. A study in the Journal of Clinical Psychopharmacology highlights the GeneSight Psychotropic Test’s association with reduced psychiatric hospitalizations among patients with major depressive disorder. This test aids healthcare providers in personalizing medication choices, potentially improving treatment outcomes. In leadership changes, Myriad Genetics appointed Brian Donnelly as the new Chief Commercial Officer, effective May 2025, with expectations to drive growth and enhance product adoption.
Analysts have been revising their outlooks on Myriad Genetics as well. Scotiabank (TSX:BNS) reduced its price target for the company to $20, maintaining a Sector Outperform rating, citing low single-digit revenue growth forecasts due to policy changes but expecting strong growth in other business segments. Piper Sandler upgraded the stock to Overweight, raising the price target to $12.50, viewing the recent stock value decline as a potential opportunity for investors. Meanwhile, Morgan Stanley (NYSE:MS) adjusted its price target to $16, maintaining an Equalweight rating, following Myriad’s fourth-quarter results and noting challenges such as the CEO transition and integration of Electronic Medical (TASE:BLWV) Records.
These developments underscore Myriad Genetics’ ongoing efforts to navigate market challenges and capitalize on growth opportunities within the molecular diagnostics sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.